A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes

Clinical Microbiology and Infection

Volumn 9, Issue 2, 2003, Pages 120-132

  Kronvall, Goran ^a   Kahlmeter, G ^b   Myhre, E ^c   Galas, M F ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

Author keywords

Antibiotic resistance; Antibiotic susceptibility testing; Disk diffusion test; Surveillance; Zone histogram

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFADROXIL; CEFOTAXIME; CEFTAZIDIME; CEFTIBUTEN; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; IMIPENEM; LORACARBEF; MECILLINAM; NALIDIXIC ACID; NETILMICIN; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PIPERACILLIN; RIFAMPICIN; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CALIBRATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIFFUSION; ESCHERICHIA COLI; HISTOGRAM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SPECIES DIFFERENCE; STANDARDIZATION; STAPHYLOCOCCUS AUREUS; VALIDATION PROCESS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0038071961     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00546.x     Document Type: Article

References (31)

1. Gruneberg RN, Felmingham D. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996; 25: 169-81.
2. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42: 1762-70.
3. Fridkin SK, Steward CD, Edwards JR et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999; 29: 245-52.
4. Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int J Antimicrob Agents 1999; 13: 117-25.
5. Kahlmeter G. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000; 46(suppl A): 15-22.
6. Salun DF. Information technology: a means for enhancing surveillance of antimicrobial resistance. Clin Microbiol Newslett 2001; 21: 169-72.
7. Sahm DF, Critchley IA, Kelly LJ et al, Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2001; 45: 267-74.
8. Kronvall G, Ringertz S, Karlsson I, Göransson E, Dornbusch K. Laboratory- and species-specific interpretive breakpoints for disk diffusion tests of chloramphenicol susceptibility of Haemophilus influenzae. Antimicrob Agents Chemother 1988; 32: 1484-9.
9. Kronvall G, Ringertz S. Antibiotic disk diffusion testing revisited. Single strain regression analysis. APMIS 1991; 99: 295-306.
10. Kronvall G, Rylander M, Walder M et al. Calibration of disk diffusion antibiotic susceptibility testing: species-related trovafloxacin interpretive zone break-points and selection of disk potency. Scand J Infect Dis 1999; 31: 573-8.
11. Kronvall G, Ringertz S, Nyström S, Rylander M, Theodorsson E. Comparison of 30 ug and 120 ug gentamicin disks for the prediction of gentamicin resistance in Enterococcus faecalis. APMIS 1991; 99: 887-92.
12. Murray PR, Baron EJ, Pfaller MA et al., eds. Manual of clinical microbiology, 7th edn. Washington, DC: ASM Press, 1999: 1-1173.
13. Crichton PB, Collee JG, Fraser AG, Marmion BP, Simmons A, eds. Mackie and McCartney, practical medical microbiology, 14th edn. New York: Churchill Livingstone, 1996: 369.
14. Cowan ST, Steel KJ, Barrow GI, Feltham RKA, eds. Cowan and Steel's manual for the identification of medical bacteria, 3rd edn. Cambridge: Cambridge University Press, 1993.
15. Olsson-Liljequist B, Larsson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis Suppl 1997; 105: 13-23.
16. Ringertz S, Olsson-Liljequist B, Kahlmeter G, Kronvall G. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter break-points to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis Suppl 1997; 105: 8-12.
17. Finney DJ. Probit analysis. A statistical treatment of the sigmoid response curve. Cambridge: Cambridge University Press, 1947.
18. O'Brien TF. Global surveillance of antibiotic resistance. N Engl J Med 1992; 326: 339-40.
19. O'Brien TF, Acar JF, Medeiros AA, Norton RA, Goldstein F, Kent RL. International comparison of prevalence of resistance to antibiotics. JAMA 1978; 239: 1518-23.
20. Kiehlbauch JA, Hannett GE, Salfinger M, Archinal W, Monserrat C, Carlyn C. Use of the National Committee for Clinical Laboratory Standards Guidelines for disk diffusion susceptibility testing in New York State laboratories. J Clin Microbial 2000; 38: 3341-8.
21. Scriver SR, Hoban DJ, McGeer A, Moore TC, Walmsley SL, Low DE. Surveillance of susceptibility testing methodologies for Haemophilus influenzae in Canada, including evaluation of disk diffusion test. J Clin Microbiol 1994; 32: 2013-15.
22. Tenover FC, Mohammed MJ, Stelling J, O'Brien T, Williams R. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J Clin Microbiol 2001; 39: 241-50.
23. Vandepitte J, El-Nageh MM, Tikhomirov E et al. Guidelines for antimicrobial resistance surveillance. Alexandria: World Health Organization, Regional Office for the Eastern Mediterranean, 1996.
24. Kronvall G, Runehagen A. Improved determination of antibiotic susceptibility of bacteria using species-related SIR interpretation. Läkartidningen 1981; 78: 3483-5.
25. Moellering Jr RC, Kunz LJ. Determination of susceptibility of 24,108 gram-negative bacteria to tobramycin and other antibiotics utilizing a computerized system with electronic zone analyzer. In: Selected Proceedings from the Eighth International Congress of Chemotherapy, Athens, September, 1973. Athens: Excerpta Medica, 1974: 72-8.
26. Medeiros AA, Crellin J. Evaluation of the Sirscan automated zone reader in a clinical microbiology laboratory. J Clin Microbiol 2000; 38: 1688-93.
27. Sánchez MA, Sánchez Del Saz B, Loza E, Baquero F, Cantón R. Evaluation of the OSIRIS video reader system for disk diffusion susceptibility test reading. Clin Microbiol Infect 2001; 7: 352-7.
28. Livermore DM, Threlfall EJ, Reacher MH et al. Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing. J Antimicrob Chemother 2000; 45: 205-11.
29. Williams JD. The correlation of in-vitro susceptibility tests with in-vivo results of antibiotic treatment. Scand J Infect Dis Suppl 1978; 13: 64-6.
30. O'Brien TF, Stelling JM. WHONET: removing obstacles to the full use of information about antimicrobial resistance. Diagn Microbiol Infect Dis 1996; 25: 162-8.
31. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis 1997; 24(suppl 1): S157-68.